HAEMONETICS CORP — Director's Dealing 2017

Jun 8, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2017-06-06

Reporting Person: Simon, Christopher (President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-06	Common Stock	A	25516	$41.64	Acquired	131383	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-06	Non-qualified Stock Option (Right to Buy)	$41.64	A	104516	Acquired	2024-06-06	Common Stock (104516)	Direct

Footnotes

F1: Restricted Stock Unit grants which vest 25% per year over 4 years following the grant date. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.

F2: Grants of right to buy shares of common stock which are exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.